Palbociclib: observed
73 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingNCT07856225Report a problem
- Real-world Studies of CDK4/6 InhibitorsRecruitingNCT07407439Report a problem
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingNCT07347600Report a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyRecruitingNCT06805812Report a problem
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsRecruitingNCT06388122Report a problem
- Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.Not yet recruitingNCT06338644Report a problem
- A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 InhibitorsRecruitingNCT06171360Report a problem
- Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer PatientsNot yet recruitingNCT06076772Report a problem
- To Identify Primary Resistance to CDK4/6 Inhibitors in Breast CancerRecruitingNCT04660435Report a problem
- A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.CompletedNCT06307457Results postedReport a problem
- Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.CompletedNCT06086340Results postedReport a problem
- A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast CancerCompletedNCT05584644Results postedReport a problem
- A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in DenmarkCompletedNCT05452798Results postedReport a problem
- Real-World Effectiveness of Palbociclib in Combination With an Aromatase InhibitorCompletedNCT05361655Results postedReport a problem
- Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.CompletedNCT05155566Results postedReport a problem
- Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in JapanCompletedNCT05153187Results postedReport a problem
- Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor AloneCompletedNCT05012644Results postedReport a problem
- Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBCCompletedNCT04937660Results postedReport a problem
- Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus LetrozoleCompletedNCT04735367Results postedReport a problem
- A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.CompletedNCT04671615Results postedReport a problem
- Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.CompletedNCT04460911Results postedReport a problem
- RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.CompletedNCT04460898Results postedReport a problem
- Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination TherapyCompletedNCT04394247Results postedReport a problem
- Real-world Treatment Patterns and Effectiveness of Palbociclib and AI TherapyCompletedNCT04176354Results postedReport a problem
- UK Ibrance Patient Program (IPP) StudyCompletedNCT03921866Results postedReport a problem
- Palbociclib in Real World PracticeCompletedNCT03280303Results postedReport a problem
- Ibrance Real World InsightsCompletedNCT03159195Results postedReport a problem
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02154490Results postedReport a problem
- A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 InhibitorsCompletedNCT07512063Report a problem
- Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer PatientsActive, not recruitingNCT07493291Report a problem
- Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in PortugalCompletedNCT07223476Report a problem
- Emulation of the PALOMA-2 TrialCompletedNCT07178743Report a problem
- A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese MarketCompletedNCT07096024Report a problem
- Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) StudyActive, not recruitingNCT07008508Report a problem
- A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world DatabaseCompletedNCT06962969Report a problem
- A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in AustraliaCompletedNCT06624020Report a problem
- CARE Initiative: Real-world Emulation of the PALOMA-2 TrialCompletedNCT06607601Report a problem
- Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)CompletedNCT06525675Report a problem
- A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerActive, not recruitingNCT06495164Report a problem
- Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL StudyCompletedNCT06463626Report a problem
- Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast CancerCompletedNCT06367335Report a problem
- Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast CancerActive, not recruitingNCT06344780Report a problem
- Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.TerminatedNCT06126003Report a problem
- A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other OrgansCompletedNCT06003114Report a problem
- A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)CompletedNCT05912933Report a problem
- A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)CompletedNCT05709158Report a problem
- Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBCCompletedNCT05505175Report a problem
- Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in JapanCompletedNCT05399329Report a problem
- Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABCStatus unknownNCT05343117Report a problem
- Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 InhibitorsCompletedNCT05153135Report a problem
- A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 InhibitorsCompletedNCT05141240Report a problem
- Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up PeriodStatus unknownNCT05135104Report a problem
- Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South KoreaCompletedNCT05132101Report a problem
- Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?Status unknownNCT05051956Report a problem
- European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal TherapiesCompletedNCT05043506Report a problem
- Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABCStatus unknownNCT05000736Report a problem
- Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ETCompletedNCT04992156Report a problem
- Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf RegionCompletedNCT04916509Report a problem
- Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast CancerCompletedNCT04874025Report a problem
- Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownNCT04852081Report a problem
- Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast CancerTerminatedNCT04778982Report a problem
- First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Active, not recruitingNCT04767594Report a problem
- Swedish Ibrance Registries Insights (SIRI)CompletedNCT04654208Report a problem
- Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in ChinaStatus unknownNCT04526028Report a problem
- Patterns of Treatment and Outcome of Palbociclib Plus Endocrine TherapyCompletedNCT04524728Report a problem
- TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.CompletedNCT04498481Report a problem
- Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast CancerStatus unknownNCT04289974Report a problem
- Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use ProgrameCompletedNCT04109261Report a problem
- Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®CompletedNCT03445637Report a problem
- Patterns of Prescribing and Monitoring of PalbociclibCompletedNCT03285568Report a problem
- Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine TherapyActive, not recruitingNCT03281902Report a problem
- Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed AppropriateNo longer availableNCT02142868Report a problem